Biopharma executives in Europe and Asia, together with their financial supporters, have launched a new company to develop therapies that will both activate and inhibit the function of regulatory T cells (Tregs). Tregs are white blood cells that play a key role in regulating the immune system to ensure that the body responds appropriately to foreign antigens and neoantigens. Announced on 18 October, Regimmune/Kiji TX is the result of a merger between Kiji Therapeutics of France and Regimmune Ltd of Taiwan. The Japan based venture capital group DCI Partner Co Ltd helped execute the merger.